A review of PCSK9 inhibition and its effects beyond LDL receptors

Journal of Clinical Lipidology

Volumn 10, Issue 5, 2016, Pages 1073-1080

  Dixon, Dave L ^a   Trankle, Cory ^b   Buckley, Leo ^a   Parod, Eric ^a   Carbone, Salvatore ^b,c   Van Tassell, Benjamin W ^a   Abbate, Antonio ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alirocumab; Dyslipidemia; Evolocumab; PCSK9

Indexed keywords

ALIROCUMAB; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN E; BOCOCIZUMAB; CD36 ANTIGEN; EVOLOCUMAB; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE 9; SMALL INTERFERING RNA; VACCINE; VERY LOW DENSITY LIPOPROTEIN RECEPTOR; MOLECULAR LIBRARY;

DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HYPERCHOLESTEROLEMIA; IMMUNOLOGY; METABOLISM; MOLECULAR LIBRARY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD36; HUMANS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASE 9; RECEPTORS, LDL; RNA, SMALL INTERFERING; SMALL MOLECULE LIBRARIES;

EID: 84995489912     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2016.07.004     Document Type: Review

References (65)

1. 1 Abifadel, M., Varret, M., Rabes, J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34 (2003), 154–156.
2. 2 Humphries, S.E., Whittall, R.A., Hubbart, C.S., et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 43 (2006), 943–949.
3. 3 Cohen, J.C., Boerwinkle, E., Mosley, T.H., et al. Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease. N Engl J Med 354 (2006), 1264–1272.
4. 4 Rashid, S., Curtis, D.E., Garuti, R., et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 102 (2005), 5374–5379.
5. 5 Dong, B., Wu, M., Li, H., et al. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res 51 (2010), 1486–1495.
6. 6 Jeong, H.J., Lee, H.S., Kim, K.S., et al. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res 49 (2008), 390–409.
7. 7 Careskey, H.E., Davis, R.A., Alborn, W.E., et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 49 (2008), 394–398.
8. 8 Mayne, J., Dewpura, T., Raymond, A., et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis, 7, 2008, 22.
9. 9 Seidah, N.G., Prat, A., The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11 (2012), 367–383.
10. 10 Naureckiene, S., Ma, L., Sreekumar, K., et al. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys 420 (2003), 55–67.
11. 11 McKenney, J.M., Understanding PCSK9 and anti-PCSK9 therapies. J Clin Lipidol 9 (2015), 170–186.
12. 12 Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., et al. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med 372 (2015), 1500–1509.
13. 13 Robinson, J.G., Farnier, M., Krempf, M., et al. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med 372 (2015), 1489–1499.
14. 14 Schroeder, K.M., Beyer, T.P., Hansen, R.J., et al. Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. J Lipid Res 56 (2015), 2124–2132.
15. 15 Sabatine, M.S., Giugliano, R.P., Keech, A., et al. Rationale and Design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk (FOURIER) Trial. Am Heart J 173 (2015), 94–101.
16. 16 Schwartz, G.G., Bessac, L., Berdan, L.G., et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 168 (2014), 682–689.
17. 17 Giugliano, R.P., Sabatine, M.S., Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?. J Am Coll Cardiol 65 (2015), 2638–2651.
18. 18 Fitzgerald, K., Frank-Kamenetsky, M., Shulga-Morskaya, S., et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383 (2014), 60–68.
19. 19 Fitzgerald K, Simon A, White S, et al. A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-PCSsc), Targeting PCSK9 for the Treatment of Hypercholesterolemia: Initial Phase 1 Study Results. Available at: http://www.alnylam.com/web/assets/ALN-PCSsc-Phase-1_Poster_08302015.pdf. Accessed May 2, 2016.
20. 20 van Poelgeest, E.P., Hodges, M.R., Moerland, M., et al. Antisense-mediated reduction of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial. Br J Clin Pharmacol 80:6 (2015), 1350–1361.
21. 21 van Poelgeest, E.P., Swart, R.M., Betjes, M.G.H., et al. Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis 62 (2013), 796–800.
22. 22 Gupta, N., Fisker, N., Asselin, M.C., et al. A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo. PLoS One, 5, 2010, e10682.
23. 23 Lindholm, M.W., Elmén, J., Fisker, N., et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther 20 (2012), 376–381.
24. 24 Zhang, Y., Zhou, L., Kong-Beltran, M., et al. Calcium-independent inhibition of PCSK9 by affinity-improved variants of the LDL receptor EGF(A) domain. J Mol Biol 422 (2012), 685–696.
25. 25 Zhang, Y., Eigenbrot, C., Zhou, L., et al. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J Biol Chem 289 (2014), 942–955.
26. 26 McNutt, M.C., Kwon, H.J., Chen, C., et al. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem 284 (2009), 10561–10570.
27. 27 Du, F., Hui, Y., Zhang, M., et al. Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J Biol Chem 286 (2011), 43054–43061.
28. 28 Mitchell, T., Chao, G., Sitkoff, D., et al. Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Ther 350 (2014), 412–424.
29. 29 Seidah, N.G., Poirier, S., Denis, M., et al. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One, 7, 2012, e41865.
30. 30 Galabova, G., Brunner, S., Winsauer, G., et al. Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management. PLoS One, 9, 2014, e114469.
31. 31 Crossey, E., Amar, M.J.A., Sampson, M., et al. A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine 33 (2015), 5747–5755.
32. 32 Lam, J.K.W., Chow, M.Y.T., Zhang, Y., et al. siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids, 4, 2015, e252.
33. 33 Frank-Kamenetsky, M., Grefhorst, A., Anderson, N.N., et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 105 (2008), 11915–11920.
34. 34 Shimada, Y.J., Cannon, C.P., PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur Heart J 36 (2015), 2415–2424.
35. 35 Do, R.Q., Vogel, R.A., Schwartz, G.G., PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics. Curr Cardiol Rep, 15, 2013, 345.
36. 36 Chan, J.H.P., Lim, S., Wong, W.S.F., Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 33 (2006), 533–540.
37. 37 Graham, M.J., Lemonidis, K.M., Whipple, C.P., et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 48 (2007), 763–767.
38. 38 Shan, L., Pang, L., Zhang, R., et al. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem Biophys Res Commun 375 (2008), 69–73.
39. 39 Bottomley, M.J., Cirillo, A., Orsatti, L., et al. Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J Biol Chem 284 (2009), 1313–1323.
40. 40 Zhang, D.-W., Lagace, T.A., Garuti, R., et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 282 (2007), 18602–18612.
41. 41 Mayer, G., Poirier, S., Seidah, N.G., Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem 283 (2008), 31791–31801.
42. 42 Kwon, H.J., Lagace, T.A., McNutt, M.C., et al. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A 105 (2008), 1820–1825.
43. 43 Schneeberger, A., Mandler, M., Otawa, O., et al. Development of AFFITOPE vaccines for Alzheimer's disease (AD)–from concept to clinical testing. J Nutr Health Aging 13 (2009), 264–267.
44. 44 Poirier, S., Mayer, G., Benjannet, S., et al. The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2. J Biol Chem 283 (2008), 2363–2372.
45. 45 Kysenius, K., Muggalla, P., Mätlik, K., et al. PCSK9 Regulates Neuronal Apoptosis by Adjusting ApoER2 Levels and Signaling. Cell Mol Life Sci 69 (2012), 1903–1916.
46. 46 Roubtsova, A., Munkonda, M.N., Awan, Z., et al. Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue. Arterioscler Thromb Vasc Biol 31 (2011), 785–791.
47. 47 Canuel, M., Sun, X., Asselin, M.C., et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1). PLoS One 8 (2013), 1–11.
48. 48 Giunzioni, I., Tavori, H., Covarrubias, R., et al. Local Effects of Human PCSK9 on the Atherosclerotic Lesion. J Pathol 238:1 (2016), 52–62.
49. 49 Walley, K.R., Thain, K.R., Russell, J.A., et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med, 6, 2014, 258ra143.
50. 50 Levy, E., Ben Djoudi Ouadda, A., Spahis, S., et al. PCSK9 Plays a Significant Role in Cholesterol Homeostasis and Lipid Transport in Intestinal Epithelial Cells. Atherosclerosis 227 (2013), 297–306.
51. 51 Demers, A., Samami, S., Lauzier, B., et al. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver. Arterioscler Thromb Vasc Biol 35:12 (2015), 2517–2525.
52. 52 Reddy, S.S., Connor, T.E., Weeber, E.J., et al. Similarities and Differences in Structure, Expression, and Functions of VLDLR and ApoER2. Mol Neurodegener, 6, 2011, 30.
53. 53 Kim, J., Basak, J.M., Holtzman, D.M., The Role of Apolipoprotein E in Alzheimer's Disease. Neuron 63 (2009), 287–303.
54. 54 Strickland, D.K., Gonias, S.L., Argraves, W.S., Diverse Roles for the LDL Receptor Family. Trends Endocrinol Metab 13 (2002), 66–74.
55. 55 Gardai, S.J., McPhillips, K.A., Frasch, S.C., et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123 (2005), 321–334.
56. 56 Gaultier, A., Arandjelovic, S., Niessen, S., et al. Regulation of Tumor Necrosis Factor Receptor-1 and the IKK-NF-kB Pathway by LDL Receptor-Related Protein Explains the Antiinflammatory Activity of This Receptor. Blood 111 (2008), 5316–5325.
57. 57 Benjannet, S., Rhainds, D., Essalmani, R., et al. NARC-1/PCSK9 and Its Natural Mutants: Zymogen Cleavage and Effects on the Low Density Lipoprotein (LDL) Receptor and LDL Cholesterol. J Biol Chem 279 (2004), 48865–48875.
58. 58 Bobryshev, Y.V., Monocyte recruitment and foam cell formation in atherosclerosis. Micron 37 (2006), 208–222.
59. 59 Lusis, A.J., Atherosclerosis. Nature 407 (2000), 233–241.
60. 60 Oury, C., CD36: Linking Lipids to the NLRP3 Inflammasome, Atherogenesis and Atherothrombosis. Cell Mol Immunol 11 (2014), 8–10.
61. 61 McLaren, J.E., Michael, D.R., Ashlin, T.G., et al. Cytokines, Macrophage Lipid Metabolism and Foam Cells: Implications for Cardiovascular Disease Therapy. Prog Lipid Res 50 (2011), 331–347.
62. 62 The AIM-HIGH Investigators. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med 365 (2011), 2255–2267.
63. 63 HPS2-THRIVE Collaborative Group. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N Engl J Med 371 (2014), 203–212.
64. 64 Lilly. Lilly to Discontinue Development of Evacetrapib for High-Risk Atherosclerotic Cardiovascular Disease. Available at: https://investor.lilly.com/releasedetail.cfm?ReleaseID=936130. Accessed April 9, 2016.
65. 65 Ridker, P.M., Rifai, N., Bradwin, G., et al. Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events. Eur Heart J 37 (2016), 554–560.